JP3433952B2 - シクロスポリン免疫アッセイ - Google Patents

シクロスポリン免疫アッセイ

Info

Publication number
JP3433952B2
JP3433952B2 JP35424291A JP35424291A JP3433952B2 JP 3433952 B2 JP3433952 B2 JP 3433952B2 JP 35424291 A JP35424291 A JP 35424291A JP 35424291 A JP35424291 A JP 35424291A JP 3433952 B2 JP3433952 B2 JP 3433952B2
Authority
JP
Japan
Prior art keywords
cyclosporine
cyclosporin
antibody
group
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP35424291A
Other languages
English (en)
Japanese (ja)
Other versions
JPH04316599A (ja
Inventor
ダバリアン ダリウシュ
エィチ．ベレシニ モウリーン
アレクサンダー スベットラナ
ダブリュ．フ マエ
エフ．ウルマン エドウィン
Original Assignee
デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング filed Critical デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング
Publication of JPH04316599A publication Critical patent/JPH04316599A/ja
Application granted granted Critical
Publication of JP3433952B2 publication Critical patent/JP3433952B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9493—Immunosupressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/962—Prevention or removal of interfering materials or reactants or other treatment to enhance results, e.g. determining or preventing nonspecific binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/825—Pretreatment for removal of interfering factors from sample
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/807—Hapten conjugated with peptide or protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP35424291A 1990-11-20 1991-11-20 シクロスポリン免疫アッセイ Expired - Lifetime JP3433952B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61611690A 1990-11-20 1990-11-20
US616116 1990-11-20

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2002366051A Division JP3936285B2 (ja) 1990-11-20 2002-12-18 シクロスポリン免疫アッセイ

Publications (2)

Publication Number Publication Date
JPH04316599A JPH04316599A (ja) 1992-11-06
JP3433952B2 true JP3433952B2 (ja) 2003-08-04

Family

ID=24468093

Family Applications (2)

Application Number Title Priority Date Filing Date
JP35424291A Expired - Lifetime JP3433952B2 (ja) 1990-11-20 1991-11-20 シクロスポリン免疫アッセイ
JP2002366051A Expired - Lifetime JP3936285B2 (ja) 1990-11-20 2002-12-18 シクロスポリン免疫アッセイ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2002366051A Expired - Lifetime JP3936285B2 (ja) 1990-11-20 2002-12-18 シクロスポリン免疫アッセイ

Country Status (7)

Country Link
US (3) US6190873B1 (Direct)
EP (2) EP0674178B1 (Direct)
JP (2) JP3433952B2 (Direct)
AT (1) ATE142344T1 (Direct)
CA (1) CA2055813A1 (Direct)
DE (2) DE69121844T2 (Direct)
ES (2) ES2181734T3 (Direct)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2161101A1 (en) 1993-04-23 1994-11-10 Eduardo Gonzalez Rapamycin conjugates and antibodies
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
WO1996040662A2 (en) * 1995-06-07 1996-12-19 Cellpro, Incorporated Aminooxy-containing linker compounds and their application in conjugates
US5650288A (en) * 1995-07-14 1997-07-22 Macfarlane; Gordon D. Immunophilin-bound immunosuppressant assay
EP1719781A3 (en) * 1997-08-08 2006-11-15 Dade Behring Marburg GmbH Method of introducing an amine-reactive functionality into a dextran
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
US6028183A (en) 1997-11-07 2000-02-22 Gilead Sciences, Inc. Pyrimidine derivatives and oligonucleotides containing same
US6007992A (en) * 1997-11-10 1999-12-28 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5990274A (en) * 1997-11-25 1999-11-23 Dade Behring Inc. Cyclosporine derivatives and uses thereof
US6231982B1 (en) 1997-12-10 2001-05-15 Dade Behring Inc. Particle reagents having reduced matrix effects and containing an aldehyde-reactive functional group
US6686454B1 (en) 1998-10-09 2004-02-03 Isotechnika, Inc. Antibodies to specific regions of cyclosporine related compounds
CA2343356A1 (en) 1998-10-09 2000-04-20 Isotechnika, Inc. Methods for the production of antibodies to specific regions of cyclosporine and cyclosporine metabolites
KR20020039528A (ko) * 2000-11-22 2002-05-27 조명재 사이클로스포린 7- 티오아미드 유도체를 유효성분으로하는 모발성장촉진제
US7045098B2 (en) 2001-02-02 2006-05-16 James Matthew Stephens Apparatus and method for removing interfering substances from a urine sample using a chemical oxidant
EP1436321B9 (en) 2001-10-19 2008-11-12 Isotechnika Inc. Synthesis of cyclosporin analogs
US20030109067A1 (en) * 2001-12-06 2003-06-12 Immunetech, Inc. Homogeneous immunoassays for multiple allergens
US20030022390A1 (en) * 2002-05-30 2003-01-30 Stephens James Matthew Method and kit for making interfering substances in urine undetectable
JP4200503B2 (ja) * 2002-12-26 2008-12-24 日東紡績株式会社 免疫測定法およびそれに用いるキット
JP2006524232A (ja) 2003-03-17 2006-10-26 アルバニー モレキュラー リサーチ インコーポレーティッド 新規サイクロスポリン
US8263354B2 (en) * 2004-05-30 2012-09-11 Sloan-Kettering Institute For Cancer Research Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
BRPI0510895A (pt) * 2004-05-30 2007-11-27 Sloan Kettering Inst Cancer formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
US20080188479A1 (en) * 2004-05-30 2008-08-07 Sloan-Kettering Institute For Cancer Research Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
US7226906B2 (en) * 2004-08-16 2007-06-05 Array Biopharma, Inc. Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2006039163A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Cyclosporin alkyne analogues and their pharmaceutical uses
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
EP1812037A4 (en) 2004-10-06 2009-11-11 Amr Technology Inc ALKYNES OF CYCLOSPORINE AND THEIR USEFUL AS PHARMACEUTICAL AGENTS
US8021849B2 (en) * 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
US20060216762A1 (en) 2005-03-24 2006-09-28 Bayer Healthcare Llc Extracting reagent for hydrophobic analyte in whole blood
US7189582B2 (en) * 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
WO2008121096A1 (en) * 2005-05-19 2008-10-09 The Board Of Governors For Higher Education Monitoring cyclosporine in saliva
BRPI0706575B8 (pt) * 2006-01-13 2021-05-25 Univ Indiana Res & Tech Corp uso colágeno de tipo v ou um componente antigênico do mesmo, e, método para identificar um paciente em espera de transplante de pulmão para um risco aumentado de rejeição de tecido de órgão transplantado.
US20080081379A1 (en) * 2006-07-13 2008-04-03 Sigler Gerald F Homogeneous double receptor agglutination assay for immunosuppressant drugs
US7883855B2 (en) 2006-07-21 2011-02-08 Abbott Laboratories Immunosuppressant drug extraction reagent for immunoassays
CA2673314C (en) 2006-12-29 2014-03-11 Abbott Laboratories Non-denaturing lysis reagent for use with capture-in-solution immunoassay
US7914999B2 (en) * 2006-12-29 2011-03-29 Abbott Laboratories Non-denaturing lysis reagent
CA2672972C (en) 2006-12-29 2015-06-23 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
EP2118656B1 (en) * 2006-12-29 2012-08-29 Abbott Laboratories Improved assay for immunosuppressant drugs
US8288111B2 (en) 2007-05-24 2012-10-16 Abbott Laboratories Immunoassays exhibiting reduced cross-reactivity with hydrophobic drug analyte metabolites
US7790401B2 (en) * 2007-08-06 2010-09-07 Siemens Healthcare Diagnostics Methods for detection of immunosuppressant drugs
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
WO2009026234A1 (en) * 2007-08-17 2009-02-26 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
US7910378B2 (en) * 2007-12-14 2011-03-22 Siemens Healthcare Diagnostics Inc. Methods for detection of hydrophobic drugs
US20090170218A1 (en) * 2008-01-02 2009-07-02 Dade Behring Inc. Methods for detection of cyclosporin a
US20090263839A1 (en) * 2008-04-21 2009-10-22 Board Of Trustees Of The University Of Arkansas Acetaminophen-protein adduct assay device and method
CN106892923A (zh) 2010-02-02 2017-06-27 艾洛斯治疗学有限公司 10‑炔丙基‑10‑去氮杂氨基蝶呤之光学纯非对映体以及使用所述非对映体的方法
CN102368072B (zh) * 2011-06-30 2014-09-24 同昕生物技术（北京）有限公司 检测环孢霉素a药物浓度的化学发光酶联免疫检测试剂盒
JP2015532277A (ja) 2012-09-29 2015-11-09 ノバルティス アーゲー 環状ペプチドおよび医薬としてのその使用
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
ES2754282T3 (es) 2014-02-14 2020-04-16 Bioventures Llc Aductos acetaminofén proteína y procedimientos de uso de los mismos
JP6785239B2 (ja) 2014-12-03 2020-11-18 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物
CN108794621A (zh) * 2017-05-04 2018-11-13 南开大学 环孢霉素的偶联物及其制备方法与应用
CN110736835B (zh) * 2018-07-19 2023-05-23 上海云泽生物科技有限公司 一种高灵敏度胶乳增强免疫比浊法测定全血中免疫抑制剂环孢霉素a的试剂盒
CN110174363A (zh) * 2019-01-09 2019-08-27 北京九强生物技术股份有限公司 6-磷酸葡萄糖脱氢酶突变体及其在制备检测试剂中的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
US4396542A (en) 1980-02-14 1983-08-02 Sandoz Ltd. Method for the total synthesis of cyclosporins, novel cyclosporins and novel intermediates and methods for their production
IL62965A0 (en) * 1980-07-17 1981-07-31 Scripps Miles Lab Inc Monoclonal antibodies to drugs and theri production
DE3260468D1 (en) * 1981-01-09 1984-09-06 Sandoz Ag Novel cyclosporins
CH667274A5 (de) * 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
WO1986002080A1 (en) * 1984-10-04 1986-04-10 Sandoz Ag Monoclonal antibodies to cyclosporings
US5169773A (en) 1984-10-04 1992-12-08 Sandoz Ltd. Monoclonal antibodies to cyclosporins
US4727035A (en) * 1984-11-14 1988-02-23 Mahoney Walter C Immunoassay for cyclosporin
US4764503A (en) * 1986-11-19 1988-08-16 Sandoz Ltd. Novel cyclosporins
EP0283801A3 (en) * 1987-03-27 1990-05-30 Abbott Laboratories Fluorescence polarization assay for cyclosporin a and metabolites and related immunogens and antibodies
DE3888357T2 (de) * 1987-06-22 1994-09-15 Merck & Co Inc Cyclosporin-Derivate, die eine modifizierte Aminosäure auf Stellung 8 tragen.
US5089390A (en) 1987-09-04 1992-02-18 Syntex (U.S.A.) Inc. 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
CA1340387C (en) * 1987-10-30 1999-02-09 Carol A. Schlesinger Heterobifunctional coupling agents
WO1990006763A1 (en) * 1988-12-05 1990-06-28 The Trustees Of Columbia University In The City Of New York Novel derivatives of cyclosporine a, antibodies directed thereto and uses thereof
ES2084069T3 (es) * 1990-08-15 1996-05-01 Abbott Lab Reactivos de inmunoensayo y metodo para la determinacion de ciclosporina.
CA2055812A1 (en) * 1990-11-20 1992-05-21 Carl N. Skold Method of stabilizing enzyme conjugates

Also Published As

Publication number Publication date
EP0487289B1 (en) 1996-09-04
US6190873B1 (en) 2001-02-20
US6410696B1 (en) 2002-06-25
EP0674178A2 (en) 1995-09-27
JP2003201298A (ja) 2003-07-18
EP0487289A2 (en) 1992-05-27
EP0487289A3 (Direct) 1994-02-23
DE69121844T2 (de) 1997-01-23
DE69133095D1 (de) 2002-10-02
DE69133095T2 (de) 2003-03-27
DE69121844D1 (de) 1996-10-10
JPH04316599A (ja) 1992-11-06
US6054303A (en) 2000-04-25
EP0674178A3 (en) 1996-07-10
ES2181734T3 (es) 2003-03-01
JP3936285B2 (ja) 2007-06-27
CA2055813A1 (en) 1992-05-21
ES2091301T3 (es) 1996-11-01
EP0674178B1 (en) 2002-08-28
ATE142344T1 (de) 1996-09-15

Similar Documents

Publication Publication Date Title
JP3433952B2 (ja) シクロスポリン免疫アッセイ
US5089390A (en) 2-methyl-4-hexene- and 2-methyl-4-heptene-1,2-diol derivatives
JP2902699B2 (ja) アンフェタミン類の存在を定量するための組成物および方法
US7655429B2 (en) Immunoassays for topiramate
US7189582B2 (en) Compositions and methods for detection of sirolimus
US20240159781A1 (en) Sandwich assay for small molecules
JP5232769B2 (ja) Ｃ−反応性タンパク質についての結合剤
US5445820A (en) Streptolysin O peptide antigens and methods for the determination of streptolysin antibodies
JPH09507754A (ja) 哺乳類悪性細胞の選択的メチオニン飢餓方法
US6262265B1 (en) Non-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay
EP2810072B1 (en) Compositions and methods for detection of methodone metabolite
JP3185221B2 (ja) Ｆｋ５０６結合蛋白質を認識するモノクローナル抗体，ｆｋ５０６結合蛋白質の濃度測定法，および測定用キット
CA2586466A1 (en) Topiramate analogs
JP2688759B2 (ja) シュードウリジン誘導体
JP2605418B2 (ja) ハプテンである抗原に対し高親和性を持つ抗体
JPH10114797A (ja) ヒト血清アルブミン結合型ホモシステインの検出法
JPH06279494A (ja) リポタンパク質（ａ）ペプチドおよびその使用
JPH0376423B2 (Direct)
JPS62501582A (ja) 抗体製剤及びその製法と使用
JPH05308993A (ja) モノクローナル抗体、その製造法および用途
FR2664904A1 (fr) Moyens pour le diagnostic d'acide thioctique et d'anticorps anti-acide thioctique et applications biologiques.
JPWO1996018102A1 (ja) Ｆｋ５０６結合蛋白質濃度測定法

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090530

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100530

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100530

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110530

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110530

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120530

Year of fee payment: 9

EXPY Cancellation because of completion of term
FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120530

Year of fee payment: 9